BACKGROUND: CD43 is a transmembrane glycoprotein expressed in different hematopoietic cells, including some subsets of B lymphocytes. About a quarter of diffuse large B-cell lymphomas (DLBCLs) express CD43, but its prognostic significance is unknown. PATIENTS AND METHODS: We analyzed the prognostic effect of immunohistochemically determined CD43 expression in 119 patients with newly diagnosed DLBCL. All were treated with CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone)-like chemotherapy, 57 without and 62 with rituximab. RESULTS: A total of 31 DLBCL cases (26%) expressed CD43. Patients with CD43+ and CD43- lymphomas did not differ regarding sex, International Prognostic Index (IPI) factors and score, rituximab treatment, presence of bulky disease, or germinal center subtype. Median follow-up was 45 months. Patients with CD43+ DLBCL had significantly lower complete response rates (59% vs. 80%; P = .019), 2-year event-free survival (EFS) rates (34% vs. 64%; P = .003), and overall survival (OS) rates (45% vs. 76%; P = .002). The prognostic significance of CD43 expression was retained in multivariate analysis (relative risk [RR] 2.04; P = .013 for EFS; RR 2.17; P = .016 for OS). In subgroup analysis, the effect of CD43 expression was significant in patients treated with rituximab and those with low IPI, whereas it was not reached in patients treated without rituximab. The effect was not observed in patients with high IPI. CONCLUSION: These results indicate that CD43 expression is an important independent adverse prognostic factor in DLBCL.
BACKGROUND:CD43 is a transmembrane glycoprotein expressed in different hematopoietic cells, including some subsets of B lymphocytes. About a quarter of diffuse large B-cell lymphomas (DLBCLs) express CD43, but its prognostic significance is unknown. PATIENTS AND METHODS: We analyzed the prognostic effect of immunohistochemically determined CD43 expression in 119 patients with newly diagnosed DLBCL. All were treated with CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone)-like chemotherapy, 57 without and 62 with rituximab. RESULTS: A total of 31 DLBCL cases (26%) expressed CD43. Patients with CD43+ and CD43- lymphomas did not differ regarding sex, International Prognostic Index (IPI) factors and score, rituximab treatment, presence of bulky disease, or germinal center subtype. Median follow-up was 45 months. Patients with CD43+ DLBCL had significantly lower complete response rates (59% vs. 80%; P = .019), 2-year event-free survival (EFS) rates (34% vs. 64%; P = .003), and overall survival (OS) rates (45% vs. 76%; P = .002). The prognostic significance of CD43 expression was retained in multivariate analysis (relative risk [RR] 2.04; P = .013 for EFS; RR 2.17; P = .016 for OS). In subgroup analysis, the effect of CD43 expression was significant in patients treated with rituximab and those with low IPI, whereas it was not reached in patients treated without rituximab. The effect was not observed in patients with high IPI. CONCLUSION: These results indicate that CD43 expression is an important independent adverse prognostic factor in DLBCL.
Authors: Elina Alaterre; Sara Ovejero; Laurie Herviou; Hugues de Boussac; Giorgio Papadopoulos; Marta Kulis; Stéphanie Boireau; Nicolas Robert; Guilhem Requirand; Angélique Bruyer; Guillaume Cartron; Laure Vincent; Anne Marie Martinez; José Ignacio Martin-Subero; Giacomo Cavalli; Jerome Moreaux Journal: Theranostics Date: 2022-01-16 Impact factor: 11.556
Authors: Benyamin Ranjbar; Louise Bechmann Krogh; Maria Bach Laursen; Maria Nascimento Primo; Sara Correia Marques; Karen Dybkær; Jacob Giehm Mikkelsen Journal: PLoS One Date: 2016-04-05 Impact factor: 3.240
Authors: Lynn K Stanwyck; Weilin Chan; Arjun Sood; Gayatri Susarla; John Romano; Maria Pefkianaki; Kanishka Thiran Jayasundera; John R Heckenlively; Steven K Lundy; Lucia Sobrin Journal: Transl Vis Sci Technol Date: 2020-06-16 Impact factor: 3.283
Authors: Samah Kohla; Feryal A Ibrahim; Deena Mudawi; Susanna Akiki; Dina Soliman; Ahmad Al-Sabbagh; Reda R H Youssef; Mohamed A Yassin Journal: Case Rep Oncol Date: 2020-09-30